Risk factors and outcomes associated with isolation of meropenem high-level-resistant pseudomonas aeruginosa

Infection Control and Hospital Epidemiology

Volumn 30, Issue 8, 2009, Pages 746-752

  Eagye, Kathryn J ^a   Kuti, Joseph L ^a   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAPENEM; MEROPENEM;

ANTIBIOTIC SENSITIVITY; ARTICLE; ARTIFICIAL VENTILATION; BACTERIAL TRANSMISSION; BACTERIUM CULTURE; BALLOON CATHETER; CASE CONTROL STUDY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; COST OF ILLNESS; COST UTILITY ANALYSIS; DRUG SENSITIVITY; DRUG USE; FEMALE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INFECTION CONTROL; INFECTION RISK; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MULTIDRUG RESISTANCE; NONHUMAN; OUTCOME ASSESSMENT; PATIENT CODING; PREDICTION; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RISK FACTOR;

ADOLESCENT; AGE FACTORS; ANTI-BACTERIAL AGENTS; CASE-CONTROL STUDIES; CATHETERIZATION; CHILD; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; FEMALE; HEALTH CARE COSTS; HOSPITALIZATION; HOSPITALS, TEACHING; HOSPITALS, URBAN; HUMANS; LENGTH OF STAY; MALE; MICROBIAL SENSITIVITY TESTS; MULTIVARIATE ANALYSIS; ODDS RATIO; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RETROSPECTIVE STUDIES; RISK FACTORS; THIENAMYCINS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 67651113947     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/603527     Document Type: Article

References (15)

1. Gaynes R, Edwards JR. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis 2005; 41:848-854.
2. Jones RN. Resistance patterns among nosocomial pathogens: trends over the past few years. Chest 2001; 119(Suppl 2):397S-404S.
3. Fluit AC, Jones ME, Schmitz FJ, Acar J, Gupta R, Verhoef J. Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY antimicrobial surveillance program, 1997 and 1998. Clin Infect Dis 2000; 30:454-460.
4. Livermore DM. Of Pseudomonas, porins, pumps and carbapenems. J Antimicrob Chemother 2001; 47:247-250.
5. El Amin N, Giske CG, Jalal S, Keijser B, Kronvall G, Wretlind B. Carbapenem resistance mechanisms in Pseudomonas aeruginosa: alterations of porin OprD and efflux proteins do not fully explain resistance patterns observed in clinical isolates. APMIS 2005; 113:187-196.
6. Rossolini GM, Mantengoli E. Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa. Clin Microbiol Infect 2005; 11(Suppl 4):17-32.
7. Trouillet JL, Chastre J, Vuagnat A, et al. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 1998; 157:531-539.
8. Wiener J, Quinn JP, Bradford PA, et al. Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes. JAMA 1999; 281:517-\ 523.
9. Kollef MH, Fraser VJ. Antibiotic resistance in the intensive care unit. Ann Intern Med 2001; 134:298-314.
10. Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in medical intensive care units in the United States: National Nosocomial Infections Surveillance System. Crit Care Med 1999; 27:887-892.
11. Schwaber MJ, Klarfeld-Lidji S, Navon-Venezia S, Schwartz D, Leavitt A, Carmeli Y. Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition onmortality. Antimicrob Agents Chemother 2008; 52:1028-1033.
12. Harris AD, Smith D, Johnson JA, Bradham DD, Roghmann MC. Risk factors for imipenem-resistant Pseudomonas aeruginosa among hospitalized patients. Clin Infect Dis 2002; 34:340-345.
13. Lautenbach E, Weiner MG, Nachamkin I, Bilker WB, Sheridan A, Fishman NO. Imipenem resistance among Pseudomonas aeruginosa isolates: risk factors for infection and impact of resistance on clinical and economic outcomes. Infect Control Hosp Epidemiol 2006; 27:893-900.
14. Santos Filho L, Eagye KJ, Kuti JL, Nicolau DP. Addressing resistance evolution in Pseudomonas aeruginosa using pharmacodynamic modelling: application to meropenem dosage and combination therapy. Clin Microbiol Infect 2007; 13:579-585.
15. Kaye KS, Engemann JJ, Mozaffari E, Carmeli Y. Reference group choice and antibiotic resistance outcomes. Emerg Infect Dis 2004; 10:1125-1128.